

China-based Fosun Pharma and Insilico Medicine advance AI-driven drug discovery

12 January 2022 | News

The collaboration aims to combine Insilico's end-to-end AI-driven drug discovery platforms and Fosun Pharma's clinical development and commercial expertise

Shanghai Fosun Pharmaceutical (Group) Co. and Insilico Medicine have entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of artificial intelligence (AI) technology.

This strategic collaboration includes an AI-driven drug discovery research and development (R&D) collaboration on four biological targets, as well as the co-development of Insilico's QPCTL program.

Insilico will receive a total upfront payment of \$13 million for the R&D collaboration projects and the co-development of the QPCTL program, potential milestone-based payments, and share commercialization profits from the QPCTL program. In addition, Fosun Pharma will make an equity investment in Insilico.

As part of the collaboration, Fosun Pharma will secure access to Insilico's PandaOmics and Chemistry42 platforms in order to advance Fosun Pharma's internal AI-powered discovery and development efforts.